.jpg "Amarin (NASDAQ: AMRN)")
In a report released today, Leland Gershell from Oppenheimer maintained a Hold rating on Amarin (AMRN). The company’s shares closed last Wednesday at $5.04, close to its 52-week low of $3.95.
According to TipRanks.com, Gershell is a 4-star analyst with an average return of 8.1% and a 42.3% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.
Amarin has an analyst consensus of Moderate Buy, with a price target consensus of $14.75, implying a 124.5% upside from current levels. In a report released yesterday, Stifel Nicolaus also assigned a Hold rating to the stock with a $8.00 price target.
See today’s analyst top recommended stocks >>
Based on Amarin’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $135 million and net profit of $4.42 million. In comparison, last year the company earned revenue of $101 million and had a GAAP net loss of $1.82 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Amarin Corp. Plc is a biopharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. Its product development program leverages its experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. It has developed and markets Vascepa capsules through wholesale. The company was founded by Geoffrey W. Guy on March 1, 1989 and is headquartered in Dublin, Ireland.
Read More on AMRN:
